Jefferies Reiterates a 'Buy' on Catamaran (CTRX); Compelling Opportunity
Get Alerts CTRX Hot Sheet
Price: $61.47 --0%
Rating Summary:
4 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
4 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Jefferies reiterates a 'Buy' on Catamaran (NASDAQ: CTRX) price target of $117.00 (from $110.00).
Analyst, Brian Tanquilut, said, "The recent pullback in recently-renamed Catamaran Corp. (formerly SXC Health) has opened up a compelling opportunity to build positions in the stock of a company that is poised to sustain its robust growth trajectory (30%+ EPS growth for at least the next three years) and likely upside current Street expectations."
FY13 EPS estimate raised from $3.00 to $3.54.
For an analyst ratings summary and ratings history on Catamaran click here. For more ratings news on Catamaran click here.
Shares of Catamaran closed at $93.03 yesterday.
Analyst, Brian Tanquilut, said, "The recent pullback in recently-renamed Catamaran Corp. (formerly SXC Health) has opened up a compelling opportunity to build positions in the stock of a company that is poised to sustain its robust growth trajectory (30%+ EPS growth for at least the next three years) and likely upside current Street expectations."
FY13 EPS estimate raised from $3.00 to $3.54.
For an analyst ratings summary and ratings history on Catamaran click here. For more ratings news on Catamaran click here.
Shares of Catamaran closed at $93.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- argenx SE (ARGX) PT Raised to $1,353 at TD Cowen
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share